Anti-SUFU antibody [EPR23821-101] - BSA and Azide free,Abcam,AB275747
ab275747 is the carrier-free version of ab259975 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
Flow Cyt (Intra), WB
Platform ID
BAB858899468
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Negative regulator in the hedgehog/smoothened signaling pathway (PubMed : 10559945, PubMed : 10564661, PubMed : 10806483, PubMed : 12068298, PubMed : 12975309, PubMed : 15367681, PubMed : 22365972, PubMed : 24217340, PubMed : 24311597, PubMed : 27234298, PubMed : 28965847). Down-regulates GLI1-mediated transactivation of target genes (PubMed : 15367681, PubMed : 24217340, PubMed : 24311597). Down-regulates GLI2-mediated transactivation of target genes (PubMed : 24217340, PubMed : 24311597). Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome (PubMed : 10559945, PubMed : 10564661, PubMed : 10806483, PubMed : 24217340). Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein (PubMed : 10559945, PubMed : 10564661, PubMed : 10806483, PubMed : 24217340). Negative regulator of beta-catenin signaling (By similarity). Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL) (PubMed : 24311597, PubMed : 28965847). GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state (PubMed : 24311597, PubMed : 28965847). Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R (PubMed : 24311597, PubMed : 28965847). When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A) (PubMed : 24311597, PubMed : 28965847). Required for normal embryonic development (By similarity). Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity). See full target information SUFU
Category Paths
Please provide the required information below so that we can quickly source your products.